P-400ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). (2nd July 2019) - Grothey, A; Yaeger, R; Paez, D; Tabernero, J; Taïeb, J; Yoshino, T; Groc, M; Vedovato, J; Chetaille, E; Van Cutsem, E